Survey: Biotechs generally pleased with FDA performance

05/23/2007 | San Diego Union-Tribune

The biotech industry appears to be satisfied that the FDA is doing better at telling firms what it expects to see from them when submitting new products, a survey shows. Biocom and PricewaterhouseCoopers sponsored the survey that found 81% of biotechs feel the agency has been performing better since it began charging additional fees in 1997, allowing it to speed its review. About half of the companies also think more post-market drug monitoring is needed, the survey found.

View Full Article in:

San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC